The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women
Open accessAbstract
Pharmacological response depends on multiple factors and one of them is sex–gender. Data on the specific effects of sex–gender on pharmacokinetics, as well as the safety and efficacy of numerous medications, are beginning to emerge. Nevertheless, the recruitment of women for clinical research is inadequate, especially during the first phases. In general, pharmacokinetic differences between males and females are more numerous and consistent than disparities in pharmacodynamics. However, sex–gender pharmacodynamic differences are now increasingly being identified at the molecular level. It is now even becoming apparent that sex–gender influences pharmacogenomics and pharmacogenetics. Sex‐related differences have been reported for several parameters, and it is consistently shown that women have a worse safety profile, with drug adverse reactions being more frequent and severe in women than in men. Overall, the pharmacological status of women is less well studied than that of men and deserves much more attention. The design of clinical and preclinical studies should have a sex–gender‐based approach with the aim of tailoring therapies to an individual's needs and concerns. Linked Articles: This article is part of a themed section on Biological Sex and Cardiovascular Pharmacology. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue‐3
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214 · cited 1×
“…RALES (Randomized Aldactone Evaluation Study) and EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Study), it was shown that spironolactone and eplerenone, selective aldosterone antagonists, were effective at reducing mortality in heart failure patients (Pitt et al., 1999; 2003).”
BackgroundCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169 · cited 1×
“Indeed, risk factors for ADE, such as polytherapy, aging and depression, are more frequent in women than in men (Pirmohamed et al., 2004; Patel et al., 2007; Zender and Olshansky, 2009; Sikdar et al., 2010; Franconi et al., 2011b).”
BackgroundStatins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Mosca, L., Benjamin, E. J., Berra, K., Bezanson, J. L., Dolor, R. J., Lloyd-Jones, D. M., Newby, L. K., Piña, I. L., Roger, V. L., Shaw, L. J., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820faaf8 · Cited by 2,143
Sex Differences in Pharmacokinetics and Pharmacodynamics
Soldin, O. P., & Mattison, D. R. (2009) · Clinical Pharmacokinetics · doi:10.2165/00003088-200948030-00001 · Cited by 1,163 · cited 2×
“…4 + M (rat) (Huang et al., 2011) Catechol-O-methyl transferase + M Dopamine, noradrenaline, adrenaline, levodopa, azathioprine (Franconi et al., 2007; Soldin and Mattison, 2009) CYP1A2 + M Caffeine, clozapine, steroids, flutamide, lidocaine, mexiletine Inducer: coffee, smoking, charcoal-grilled…”
BackgroundInfluentialWing, L. M. H., Reid, C. M., Ryan, P., Beilin, L. J., Brown, M. A., Jennings, G. L. R., Johnston, C. I., McNeil, J. J., Macdonald, G. J., Marley, J. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021716 · Cited by 1,130 · cited 1×
“However, results from an Australian study demonstrated that ACEIs decrease CV events in men but not in women (Wing et al., 2003).”
ResultStudying sex and gender differences in pain and analgesia: a consensus report
Greenspan, J. D., Craft, R. M., LeResche, L., Arendt-Nielsen, L., Berkley, K. J., Fillingim, R. B., Gold, M. S., Holdcroft, A., Lautenbacher, S., Mayer, E. A., et al. (2007) · Pain · doi:10.1016/j.pain.2007.10.014 · Cited by 1,033
Gillies, G. E., & McArthur, S. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002071 · Cited by 733 · cited 1×
“Numerous reviews have focused on strategies and methods that optimize sex–gender research in different fields (Gillies and McArthur, 2010; Miller et al., 2011).”
BackgroundMazzaglia, G., Ambrosioni, E., Alacqua, M., Filippi, A., Sessa, E., Immordino, V., Borghi, C., Brignoli, O., Caputi, A. P., Cricelli, C., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.830299 · Cited by 637 · cited 2×
“…therapy adherence after acute coronary syndrome and myocardial infarction (Butler et al., 2002; Jackevicius et al., 2008; Lee et al., 2008; Peterson et al., 2008; Tuppin et al., 2009; Mosca et al., 2011; Kirchmayer et al., 2012; Kumbhani et al., 2013), and in hypertension (Mazzaglia et al., 2009).”
BackgroundSafety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions
Bellosta, S., Paoletti, R., & Corsini, A. (2004) · Circulation · doi:10.1161/01.cir.0000131519.15067.1f · Cited by 578
Shekelle, P. G., Rich, M. W., Morton, S. C., Atkinson, C. S. W., Tu, W., Maglione, M., Rhodes, S., Barrett, M., Fonarow, G. C., Greenberg, B., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00262-6 · Cited by 492 · cited 1×
“One meta-analysis showed that ACEIs are less effective in reducing mortality in women with symptomatic heart failure than in men, whereas these agents do not modify the survival rate in women with asymptomatic heart failure (Shekelle et al., 2003).”
BackgroundFemale sex and oral contraceptive use accelerate nicotine metabolism
BENOWITZ, N., LESSOVSCHLAGGAR, C., SWAN, G., & JACOBIII, P. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.01.008 · Cited by 486
Representation of Women in Randomized Clinical Trials of Cardiovascular Disease Prevention
Melloni, C., Berger, J. S., Wang, T. Y., Gunes, F., Stebbins, A., Pieper, K. S., Dolor, R. J., Douglas, P. S., Mark, D. B., & Newby, L. K. (2010) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.868307 · Cited by 455
Renin angiotensin system and gender differences in the cardiovascular system
Fischer, M. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00479-5 · Cited by 384 · cited 1×
“In particular, oestrogens increase the availability of angiotensinogen and plasma levels of angiotensin II, but decrease renin and ACE activities, and the expression of angiotensin receptor 1, while androgens up-regulate the RAS system (Fischer et al., 2002).”
BackgroundChronic Stress Modulates the Immune Response to a Pneumococcal Pneumonia Vaccine
Glaser, R., Sheridan, J., Malarkey, W. B., MacCallum, R. C., & Kiecolt-Glaser, J. K. (2000) · Psychosomatic Medicine · doi:10.1097/00006842-200011000-00010 · Cited by 295 · cited 1×
“Finally, some SGDs are caused by social, educational, cultural and lifestyle factors (e.g. smoking and alcohol habits), stress, access to health care and service (Glaser et al., 2000; Budesa et al., 2008).”
BackgroundElovainio, M., Ferrie, J. E., Singh-Manoux, A., Shipley, M., Batty, G. D., Head, J., Hamer, M., Jokela, M., Virtanen, M., Brunner, E., et al. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwr149 · Cited by 131
Organic anion transporters and their implications in pharmacotherapy
Emami Riedmaier, A., Nies, A. T., Schaeffeler, E., & Schwab, M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004614 · Cited by 128 · cited 1×
“Genetic polymorphisms of drug transporters have been demonstrated extensively (Buist et al., 2002; Morris et al., 2003; Groves et al., 2006; Burckhardt, 2012; Emami Riedmaier et al., 2012).”
BackgroundDiscontinuation of statin therapy due to muscular side effects: A survey in real life
Rosenbaum, D., Dallongeville, J., Sabouret, P., & Bruckert, E. (2013) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2012.04.012 · Cited by 111
Woodard-Grice, A. V., Lucisano, A. C., Byrd, J. B., Stone, E. R., Simmons, W. H., & Brown, N. J. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833d3acb · Cited by 92
Casey, D. P., Curry, T. B., Joyner, M. J., Charkoudian, N., & Hart, E. C. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.164517 · Cited by 83
Research works printed but not linked: 187
- 10.1016/j.phrs.2004.11.006 · doi:10.1016/j.phrs.2004.11.006
- 10.1111/bph.12444 · DOI · Paper page
- 10.1016/j.cbi.2010.04.002 · DOI
- 10.2165/00003088-200544100-00001 · DOI · Paper page
- 10.2217/17455057.1.2.183 · DOI
- 10.1038/sj.clpt.6100377 · DOI
- 10.3109/10623320109165322 · DOI
- 10.1007/s11095-008-9635-y · DOI
- 10.1097/PSY.0b013e31818105ed · DOI
- 10.1097/PSY.0b013e3182080d73 · DOI
- 10.1186/2191-219X-2-57 · DOI
- 10.2174/138920009788498996 · DOI
- 10.1016/S0001-4079(19)33352-7 · doi:10.1016/s0001-4079(19)33352-7
- 10.1371/journal.pone.0054289 · DOI · Paper page
- 10.1586/ecp.12.58 · DOI
- 10.1196/annals.1422.019 · DOI · Paper page
- 10.1378/chest.121.3.906 · DOI
- 10.1097/00062752-200009000-00005 · DOI
- 10.1182/blood-2006-03-013151 · DOI
- 10.1124/dmd.106.012070 · DOI · Paper page
- 10.1124/jpet.301.1.145 · DOI · Paper page
- 10.1016/j.pharmthera.2012.07.010 · DOI · Paper page
- 10.1016/S0735-1097(02)02379-3 · DOI · Paper page
- Campesi I, 2013, Regular cigarette smoking influences the transsulfuration pathway, endothelial function, and inflammation biomarkers in a sex‐gender specific manner in healthy young humans, Am J Transl Res, 5, 497
- 10.1161/hc4201.097834 · DOI · Paper page
- 10.1161/HYPERTENSIONAHA.111.182337 · DOI
- 10.1038/clpt.2009.89 · DOI
- 10.4158/EP.14.2.162 · DOI
- 10.1016/S0008-6363(01)00528-4 · DOI
- 10.1002/bdd.512 · DOI
- 10.1161/01.CIR.0000032002.22105.7A · DOI · Paper page
- 10.1007/BF03261926 · DOI
- 10.2165/00002018-200124080-00002 · DOI · Paper page
- 10.1016/S0008-6363(01)00527-2 · DOI · Paper page
- 10.1161/01.HYP.0000124253.98863.86 · doi:10.1161/01.hyp.0000124253.98863.86
- 10.4061/2010/164906 · DOI
- 10.1007/s00439-007-0430-3 · DOI · Paper page
- 10.1016/j.amjcard.2009.06.003 · doi:10.1016/j.amjcard.2009.06.003
- 10.1007/s10157-005-0368-5 · DOI · Paper page
- 10.1016/S1550-8579(08)80008-3 · DOI
- European Medicines Agency, 2010, Guideline on the Investigation of Bioequivalence
- 10.1345/aph.1L036 · DOI
- 10.1055/s-0038-1656045 · DOI
- FDA(2010).Evaluation of Gender Differences in Clinical Investigations – Information Sheet Guidance for Institutional Review Boards and Clinical Investigators: U. S. Department of Health and Human Services.
- 10.1016/j.jelectrocard.2003.09.054 · DOI
- 10.1016/j.phrs.2006.11.001 · DOI · Paper page
- 10.1016/j.phrs.2007.11.007 · DOI
- 10.2174/138161211795656918 · doi:10.2174/138161211795656918
- 10.4155/tde.11.117 · DOI
- 10.1007/978-3-642-30726-3_6 · DOI
- 10.1016/j.ijpharm.2011.04.069 · DOI · Paper page
- 10.1161/JAHA.112.002584 · DOI
- 10.1378/chest.11-0404 · doi:10.1378/chest.11-0404
- 10.1016/j.yjmcc.2010.06.005 · DOI · Paper page
- 10.1124/dmd.110.035345 · DOI
- 10.1146/annurev.pharmtox.44.101802.121453 · DOI · Paper page
- 10.1161/01.CIR.102.20.2473 · DOI · Paper page
- 10.1124/jpet.105.094979 · DOI
- 10.1111/j.1365-2125.1995.tb04554.x · DOI
- 10.2217/pgs.09.102 · DOI
- 10.1097/00004872-200210000-00030 · doi:10.1097/00004872-200210000-00030
- 10.1002/syn.20541 · DOI
- 10.1159/000216582 · DOI
- 10.2165/11318100-000000000-00000 · DOI · Paper page
- 10.1113/jphysiol.2010.199935 · DOI
- 10.3109/03602532.2011.567391 · DOI · Paper page
- 10.1016/j.jprot.2011.01.015 · DOI
- Institute of Medicine, 2010, Women's Health Research: Progress, Pitfalls, and Promise
- 10.1161/CIRCULATIONAHA.107.706820 · DOI · Paper page
- 10.1016/j.pbiomolbio.2005.05.010 · DOI · Paper page
- 10.1111/j.1469-7793.2001.0161m.x · DOI · Paper page
- 10.1177/0091270009359525 · DOI
- 10.1093/eurheartj/ehi397 · DOI · Paper page
- 10.1345/aph.1M147 · DOI
- 10.1038/253355a0 · DOI · Paper page
- Jones SG, 2009, Distal upper and lower limb fractures associated with thiazolidinedione use, Am J Manag Care, 15, 491
- 10.3109/08037051003768247 · DOI
- 10.1080/07853890600989211 · DOI · Paper page
- 10.1111/j.1752-8062.2009.00094.x · DOI
- 10.2165/00003495-199550010-00001 · DOI
- 10.1111/j.1365-2710.2010.01242.x · DOI
- 10.1111/j.1476-5381.2012.01922.x · DOI
- 10.1097/00004872-200018050-00017 · DOI
- 10.1002/j.1552-4604.1995.tb04039.x · doi:10.1002/j.1552-4604.1995.tb04039.x
- 10.1016/S0002-9149(97)89205-3 · DOI
- 10.1016/S0735-1097(00)00849-4 · DOI · Paper page
- 10.1016/j.taap.2012.04.001 · DOI
- 10.1016/j.jacc.2012.03.081 · doi:10.1016/j.jacc.2012.03.081
- 10.1016/j.jacc.2011.09.067 · DOI · Paper page
- 10.1111/j.1469-8986.1981.tb01840.x · DOI
- 10.1067/mcp.2000.109356 · DOI
- 10.1081/NCN-200027624 · doi:10.1081/ncn-200027624
- 10.1016/j.cca.2009.04.010 · DOI
- 10.1016/j.amjmed.2012.02.025 · DOI
- 10.1248/bpb.b212021 · DOI
- Kurrelmeyer K, 2003, Platelet hyperreactivity in women from families with premature atherosclerosis, J Am Med Womens Assoc, 58, 272
- 10.18553/jmcp.2008.14.3.271 · DOI
- Legato MJ, 2009, Principles of Gender‐Specific Medicine
- 10.1172/JCI200319429 · DOI
- 10.1124/jpet.301.2.551 · DOI
- 10.1152/ajpheart.00985.2009 · DOI
- 10.1124/dmd.107.014845 · DOI
- 10.1053/cp.1999.v66.103400001 · doi:10.1053/cp.1999.v66.103400001 · Paper page
- 10.1177/1753944712468499 · DOI
- 10.1046/j.1365-2125.1999.00855.x · DOI
- 10.1007/978-3-642-30726-3_2 · DOI
- 10.1124/dmd.31.5.637 · doi:10.1124/dmd.31.5.637
- 10.1017/S1092852913000667 · DOI · Paper page
- 10.1016/j.mam.2011.02.001 · DOI
- 10.1097/FPC.0b013e328348c6db · DOI
- 10.1096/fj.08-114348 · DOI
- 10.1126/science.1112062 · DOI · Paper page
- 10.1055/s-0031-1299774 · DOI
- 10.1016/j.genm.2008.03.009 · DOI
- 10.1186/2042-6410-2-14 · DOI
- 10.1016/S0009-9236(96)90172-1 · DOI
- 10.1136/hrt.2010.199760 · DOI
- 10.1113/jphysiol.2010.192492 · DOI
- 10.1124/pr.55.2.1 · DOI
- 10.1016/j.jacc.2011.11.008 · DOI
- 10.3109/03602539808996322 · DOI · Paper page
- 10.1016/0735-1097(94)90772-2 · DOI · Paper page
- 10.1016/j.pharmthera.2011.11.002 · DOI
- 10.1111/j.1540-8159.2006.00407.x · DOI · Paper page
- 10.1016/j.yjmcc.2009.07.016 · DOI
- 10.1016/j.amjcard.2012.12.037 · DOI · Paper page
- 10.1159/000327782 · DOI
- 10.1160/TH11-03-0178 · DOI
- 10.1111/j.1525-1373.2000.22359.x · doi:10.1111/j.1525-1373.2000.22359.x · Paper page
- Nicholas JS, 1932, The use of sodium amytal in the production of anesthesia in the rat, J Pharmacol Exp Ther, 46, 125
- 10.1016/j.taap.2004.01.010 · DOI · Paper page
- 10.1186/1472-6904-7-9 · DOI · Paper page
- 10.1016/j.ahj.2008.07.028 · DOI · Paper page
- 10.1016/j.whi.2008.09.009 · DOI
- 10.1136/bmj.329.7456.15 · DOI · Paper page
- 10.1200/JCO.1996.14.1.78 · DOI · Paper page
- 10.1161/01.ATV.0000186185.13977.94 · DOI
- 10.1016/0006-2952(58)90024-8 · DOI
- 10.1007/978-3-642-30726-3_7 · DOI
- 10.1007/978-3-642-30726-3 · DOI
- 10.1007/978-3-642-30726-3_1 · DOI
- 10.1152/ajpregu.00145.2007 · DOI
- 10.1097/HCO.0b013e328333f95f · DOI
- 10.1016/S1043-2760(01)00432-5 · DOI · Paper page
- Ross S, 1985, Placebo: Theory, Research and Mechanisms, 67
- 10.1111/j.1365-2362.2005.01556.x · DOI
- 10.2215/CJN.04140907 · DOI
- Saenz‐Campos D, 1995, Gender related pharmacokinetics of diltiazem in healthy subjects, Int J Clin Pharmacol Ther, 33, 397
- 10.1007/s002130000574 · DOI
- 10.1038/jhh.2010.74 · DOI
- Schuetz EG, 1995, Interindividual variation in expression of P‐glycoprotein in normal human liver and secondary hepatic neoplasms, J Pharmacol Exp Ther, 275, 1011, 10.1016/S0022-3565(25)12089-2 · DOI · Paper page
- 10.1046/j.1523-1755.2002.00624.x · DOI
- 10.1038/sj.clpt.6100226 · DOI · Paper page
- 10.1007/978-3-642-30726-3_11 · DOI
- 10.1016/S0002-9343(00)00529-5 · DOI
- 10.2165/00003088-198815020-00002 · DOI
- 10.1345/aph.1M416 · DOI
- 10.1001/jama.1988.03410070095035 · DOI · Paper page
- 10.1155/2011/187103 · DOI · Paper page
- 10.1007/978-3-642-30726-3_5 · DOI
- 10.1016/j.socscimed.2011.05.033 · DOI · Paper page
- 10.2459/JCM.0b013e328324991c · DOI
- 10.1093/eurheartj/ehi819 · DOI · Paper page
- 10.1016/j.acvd.2009.02.005 · DOI
- 10.1093/eurheartj/ehn427 · DOI · Paper page
- 10.1586/erc.09.155 · DOI
- 10.1177/1741826710389369 · DOI
- 10.1182/blood-2012-01-405498 · DOI
- 10.1161/01.HYP.0000124251.06056.8e · DOI
- 10.1093/eurpub/ckq155 · DOI
- 10.1016/j.jacc.2011.09.075 · DOI
- 10.1124/mol.109.056705 · DOI · Paper page
- 10.1016/j.curobgyn.2005.03.005 · doi:10.1016/j.curobgyn.2005.03.005
- 10.1056/NEJM199604253341703 · DOI · Paper page
- 10.1111/j.1365-2125.1994.tb04308.x · DOI
- Wolbrette D, 2002, Gender differences in the proarrhythmic potential of QT‐prolonging drugs, Curr Womens Health Rep, 2, 105
- 10.1016/S0378-4274(01)00263-6 · doi:10.1016/s0378-4274(01)00263-6
- 10.1016/S0304-3835(02)00435-4 · DOI
- 10.1182/blood-2005-03-1290 · DOI · Paper page
- 10.1007/BF03188796 · DOI
- 10.1016/j.cnur.2009.06.002 · DOI
- 10.4161/epi.6.5.15335 · DOI · Paper page
- 10.1371/journal.pone.0023506 · DOI · Paper page
- 10.1002/jat.1698 · DOI
- 10.1124/dmd.109.028209 · DOI
- 10.1080/09603123.2011.634389 · doi:10.1080/09603123.2011.634389
- 10.1055/s-0037-1613827 · doi:10.1055/s-0037-1613827
Cited by
Sex differences in pharmacokinetics predict adverse drug reactions in women
Zucker, I., & Prendergast, B. J. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00308-5 · Cited by 777
Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes
(2016) · European Heart Journal · doi:10.1093/eurheartj/ehv598 · Cited by 739
Sex and gender differences and biases in artificial intelligence for biomedicine and healthcare
Cirillo, D., Catuara-Solarz, S., Morey, C., Guney, E., Subirats, L., Mellino, S., Gigante, A., Valencia, A., Rementeria, M. J., Chadha, A. S., et al. (2020) · npj Digital Medicine · doi:10.1038/s41746-020-0288-5 · Cited by 553
Integrating Artificial Intelligence and Nanotechnology for Precision Cancer Medicine
Adir, O., Poley, M., Chen, G., Froim, S., Krinsky, N., Shklover, J., Shainsky‐Roitman, J., Lammers, T., & Schroeder, A. (2020) · Advanced Materials · doi:10.1002/adma.201901989 · Cited by 496
Gender differences in the effects of cardiovascular drugs
Tamargo, J., Rosano, G., Walther, T., Duarte, J., Niessner, A., Kaski, J., Ceconi, C., Drexel, H., Kjeldsen, K., Savarese, G., et al. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw042 · Cited by 317
Metadata
- Authors
- Franconi, F., & Campesi, I.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2014-01-13
- Volume
- 171
- Issue
- 3
- Pages
- 580-594
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2121841953
- Cited by
- 251
- References
- 22
- FWCI
- 10.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.